ABSTRACT
Os inibidores de BRAF (iBRAFs) e de MEK (iMEK), inauguraram uma nova classe de medicamentos, a terapia direcionada, no combate ao melanoma metastático. Entretanto, os pacientes adquirem resistência ao tratamento em poucos meses. Além disso, a imunoterapia vem ganhando espaço no tratamento do câncer, incluindo o melanoma, porém, com alguns aspectos inexplorados. Dentro deste tema, a enzima IDO vem despertando um grande interesse pela participação nos mecanismos de imunotolerância, imunoescape e progressão tumoral. A IDO é responsável pelo consumo e depleção do triptofano, produzindo a quinurenina. Ela está presente em diversos tipos celulares, incluindo células do sistema imune e células tumorais. Este trabalho objetivou avaliar a expressão de IDO durante a progressão da doença - desde do nevo até o melanoma metastático e também avaliar a regulação de IDO induzido por IFN-γ após tratamento com iBRAF em linhagens parentais e resistentes ao iBRAF, buscando-se os mecanismos moleculares. Por fim, objetivou-se entender os efeitos do 1-metil-triptofano (1-MT), um inibidor de IDO, tanto na sua capacidade de inibir a atividade de IDO quanto na sua influência na capacidade clonogênica. O estudo de bioinformática sobre o repositório público GSE12391 mostrou que o nível de expressão gênica de IDO foi superior nos estágios mais avançado da doença. Além disso, todas amostras de melanoma primário de pacientes apresentaram a imunomarcação de IDO, enquanto que nenhuma amostra de nevo apresentou tal marcação. Adicionalmente, a ocorrência de IDO se deu nos infiltrados linfoides, em células mononucleares do sistema imune. Duas análises de bioinformática de expressão gênica demonstraram que a IDO estava expressa positivamente na fase de resistência ao iBRAF. Ademais, os resultados de expressão proteica mostraram que a inibição de via MAPK (tanto por iBRAF quanto por iMEK) conseguiu modular a expressão de IDO, sendo que a maioria das linhagens apresentou uma diminuição de IDO. A atividade de IDO, medida através da produção de quinurenina, por HPLC se mostrou em consonância com os resultados de expressão proteica, exceto pela linhagem WM164 que não apresentou atividade enzimática, embora a proteína estivesse presente. Por fim, o 1-MT conseguiu inibir de maneira eficiente a enzima IDO, bloqueando a produção de quinurenina. Além de que, o 1-MT reduziu a capacidade clonogênica de maneira dose-dependente. Portanto, conclui-se que a expressão de IDO é crescente conforme a progressão do melanoma, que a inibição da via MAPK regulou a expressão de IDO e que o 1-MT reduz a capacidade clonogênica, além da sua função primária de inibir IDO
BRAF and MEK inhibitors (BRAFi and MEKi) has launched a new class of medication, the target therapy, to combat metastatic melanoma. Nevertheless, patients acquired resistance to the treatment in few months. Additionally, immunotherapy has been gaining space in cancer treatment, including melanoma, but some aspects need to be explored. Inside this theme, IDO enzyme has called the attention due to its participation in the mechanisms of immune tolerance, scape and tumor progression. IDO is responsible for tryptophan consume e depletion, producing kynurenine. It is present in different cells, including cells from immune system and tumor cells. This work purposed evaluate IDO expression during disease progression - since nevus until metastatic melanoma and also, evaluate IFN-γ-induced IDO regulation after BRAFi treatment in parental and resistant melanoma cell lines, seeking the molecular mechanisms. Lastly, it was evaluated the effects of 1-methyltryptopahn (1-MT), an IDO inhibitor, by its ability to inhibit IDO and also by its influency on the clonogenic capability. Bioinformatic study performed on GSE12391 showed that gene expression level of IDO was superior in the most advanced stages of the disease. Additionally, all sample of patient's primary melanoma presented IDO immunostaining, whereas, no nevus samples presented such staining. Besides, IDO occurrence was in the lymphoid infiltrates, in mononuclear cells from immune system. Two bioinformatic analysis of gene expression demonstrated that IDO was differentially overexpressed during BRAFi resistance stage. Moreover, protein expression results presented that MAPK pathway inhibition (both by BRAFi and by MEKy) was able to modulate IDO expression, and most of the cell lines presented an IDO downregulation. IDO activity, measured through kynurenine production, by HPLC was consonant with protein expression results, except by WM164 cell line, which did not present enzymatic activity, albeit the protein was present. By the end, 1-MT could inhibit efficiently IDO enzyme, blocking kynurenine production. Furthermore, 1-MT reduced clonogenic capability in a dosedependent manner. Therefore, it was concluded that IDO expression increases along with melanoma progression, MAPK pathway inhibition regulated IDO expression and 1-MT reduced clonogenic capability, besides its primary function of IDO inhibitor
Subject(s)
Disease Progression , Indoleamine-Pyrrole 2,3,-Dioxygenase/analysis , Melanoma/prevention & control , Computational Biology/instrumentation , Mitogen-Activated Protein Kinases/analysisABSTRACT
Objective To investigate the inhibitory effect and underlying mechanism of mesenchymal stem cell (MSC) derived from different sources on follicular helper T cell (Tfh cell). Methods Umbilical cord-derived MSC (UC MSC), bone marrow-derived MSC (BM MSC) and fat-derived MSC (Fat MSC) were co-cultured with peripheral blood mononuclear cell (PBMC) for 48 h. A control group was established. Flow cytometry was adopted to calculate the proportion of Tfh cells among the lymphocytes in four groups. The content of interleukin (IL)-21 in the supernatant was detected by enzyme-linked immune absorbent assay (ELISA) in four groups. BM MSC was co-cultured with PBMC, and supplemented with indoleamine 2,3-dioxygenase (IDO) inhibitor 1-methyl tryptophan (1-MT), IL-10 antibody, human leukocyte antigen (HLA)-G antibody in the 1-MT group, IL-10 inhibition group, HLA-G inhibition group and BM MSC group without addition of other substances. After 48 h culture, flow cytometry was used to detect the percentage of Tfh cells among lymphocytes. Results Flow cytometry demonstrated that compared with the control group, the proportion of Tfh cells in the BM MSC group was significantly decreased (P<0.05). Compared with the BM MSC group, the percentage of Tfh cells in the UC MSC and Fat MSC groups was significantly higher (both P<0.05). ELISA revealed that compared with the control group, the IL-21 content in the BM MSC group was significantly decreased (P<0.05). Compared with the BM MSC group, the IL-21 contents were considerably higher in the UC MSC and Fat MSC groups (both P<0.05). The analysis of underlying mechanism revealed that the proportions of Tfh cells in the 1-MT, IL-10 inhibition and the HLA-G inhibition groups were (1.75±0.07)%, (1.31±0.09)% and (1.50±0.03)%, respectively, which were significantly higher than (1.03±0.43)% in the BM MSC group (all P<0.05). Conclusions BM MSC exerts the highest inhibitory effect upon the differentiation of Tfh cell and IL-21. The mechanism underlying suppressing the differentiation of Tfh cells differentiation is probably correlated to promoting the secretion of IDO.
ABSTRACT
Objective:To explore the correlation of tyrosine phosphatase-1/2 (SHP-1,SHP-2) with indoleamine 2,3-dioxygenase(IDO) in maternal fetal interface.Methods: The expression of SHP-1,SHP-2 and IDO were detected by Western blot method and the relationship of the proteins was analysed,in human chorionic villi and decidua tissues of 30 cases of artificial abortion patients.Results:The expression of SHP-1,SHP-2 were positively correlated withthe expression of IDO in human chorionic villi and de-cidua;the expression of SHP-1,SHP-2 and IDO in decidual tissues were higher than those in the villi.Conclusion: Normal physiological state of pregnancy,SHP-1 and SHP-2 may be involved in the regulation of immune tolerance by positive regulation of IDO expression at maternal fetal interface.
ABSTRACT
OBJECTIVE: Indoleamine 2, 3-dioxygenase (IDO), an immuno suppression enzyme, is one of the initial and rate-limiting enzymes involved in the catabolism of the essential amino acid tryptophan. IDO inhibits T cell proliferation, induces T cell apoptosis, and plays a fundamental role in autoimmunity and allergy. We investigated which subtype of dendritic cells (DCs) is involved in IDO expression and the generation of regulatory T cells during the induction of oral tolerance in type II collagen-induced arthritis (CIA). METHODS: Type II Collagen was fed to DBA/1J mice before immunization. Changes in DC subtypes and induction of regulatory T cell in orally tolerized CIA mice were analyzed. Whether the effect of DC subtype was modulated by the IDO expression, was determined by flow cytometry (FACs) and confocal microscopy. RESULTS: IDO expression of CD11c+ DCs was higher in orally tolerized CIA mice than in non-tolerized CIA mice. CD11b+ DCs of the CD11c +DCs, subtype was higher in the induction of in IDO expression. Our data suggest that these IDO expressing DCs of oral tolerized mice suppressed type II collagen-specific T cell proliferation and favored the differentiation of naive CD4+ T cells into regulatory T cells. Especially, CD11c+CD11b+ DCs expressed IDO, which is known to be associated with regulatory T cell induction. CONCLUSION: We observed that oral tolerance induced the increase in IDO-expressing CD11c+CD11b+ DCs, which appeared to induce regulatory T cells. IDO-expressing CD11c+CD11b+ DCs are involved in oral tolerance, which may provide a new therapeutic approach for the treatment of rheumatoid arthritis.
Subject(s)
Mice , AnimalsABSTRACT
PURPOSE: Hematopoietic stem cells from umbilical cord blood are one of the useful resources for stem cell transplantation in the various adult and childhood diseases. Immunologic complications of transplantation, e.g., graft-vs-host disease, occur much less with transplantation of cord blood stem cells. Cord blood-derived dendritic cells (CB-DCs) are known to be different from adult peripheral blood-derived dendritic cells (PB-DCs) in immunologic characteristics. These phenomena might be related to the characteristics of hematopoietic cells in cord blood. Therefore, we analysed characteristics of dendritic cells, which are well-known immune-provoking cells, derived from cord blood precursors. METHODS: Dendritic cells were differentiated from plastic-adherent cord blood monocytes in the presence of GM-CSF and IL-4. Immunophenotype was analysed by flow cytometry and expression of IDO (indoleamine 2, 3-dioxygenase), an enzyme expressed in immune-regulating or tolerogenic DCs, IL-12, IL-10 and IL-6 was measured by RT-PCR along in vitro differentiation. Changes in expression of cytokines and IDO after antibody engagement were also analysed. RESULTS: CB-DCs were very similar to PB-DCs in immunophenotype and expression of cytokines. But CB-DCs expressed IDO transcripts much earlier than PB-DCs during differentiation from precursors. Engagement of CB-DCs with DU-1 mAb induced upregulation of IDO and downregulation of IL-6. CONCLUSION: Although immunophenotype and cytokine expression pattern of CB-DCs were quite similar to those of PB-DCs, CB-DCs expressed IDO earlier than PB-DCs. This might be related to the phenomena that CB-DCs are less immunogenic or, sometimes, tolerance-inducing.